Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

Single arm study (n=63) found an overall response rate of 90.5% and a major response rate of 79.4% for ibrutinib at 420 mg per day. The 5-year overall survival rate for all patients was 87%. Response depth was impacted by mutation status.


Journal of Clinical Oncology